06:54 AM EDT, 10/16/2025 (MT Newswires) -- Sanofi ( SNY ) has signed a collaboration and license agreement with EVOQ Therapeutics on research activities related to autoimmune diseases, EVOQ said Thursday.

Under the terms of the deal, Sanofi ( SNY ) will be responsible for the development and the commercialization efforts globally. EVOQ is eligible to receive more than $500 million in upfront, preclinical, development and sales milestones, as well as tiered royalties on product sales, the company said.

Sanofi ( SNY ) shares were up 1.3% in recent premarket activity.